ParkinsonCanadaV1, Main, Exploration, bibRecord, 003326

Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease

Identifieur interne : 003326 ( Main/Exploration ); précédent : 003325; suivant : 003327

Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease

Auteurs : Raul De La Fuente-Fernandez [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]

Source :

Science : (Washington, D.C.) [ 0036-8075 ] ; 2001.

RBID : Pascal:01-0457641

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Libération, Dopamine, Corps strié, Voie nigrostriatale, Effet placebo, Traitement, Chimiothérapie, Placebo, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Apomorphine (administration & dosage), Apomorphine (therapeutic use), Chemotherapy, Corpus Striatum (diagnostic imaging), Corpus Striatum (metabolism), Corpus striatum, Dopamine, Dopamine (metabolism), Female, Human, Humans, Male, Middle Aged, Nigrostriatal pathway, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Placebo, Placebo Effect, Placebo effect, Placebos (administration & dosage), Raclopride (metabolism), Release, Synapses (metabolism), Tomography, Emission-Computed, Treatment.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Apomorphine, Placebos.
- chemical , metabolism : Dopamine, Raclopride.
- chemical , therapeutic use : Antiparkinson Agents, Apomorphine.
- diagnostic imaging : Corpus Striatum.
- drug therapy : Parkinson Disease.
- metabolism : Corpus Striatum, Parkinson Disease, Synapses.
- Aged, Female, Humans, Male, Middle Aged, Placebo Effect, Tomography, Emission-Computed.

Abstract

The power of placebos has long been recognized for improving numerous medical conditions such as Parkinson's disease (PD). Little is known, however, about the mechanism underlying the placebo effect. Using the ability of endogenous dopamine to compete for [¹¹C]raclopride binding as measured by positron emission tomography, we provide in vivo evidence for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo. Our findings indicate that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system.

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease</title>
<author><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 285</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 285</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0457641</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0457641 INIST</idno>
<idno type="RBID">Pascal:01-0457641</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C13</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000110</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000B07</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B07</idno>
<idno type="wicri:doubleKey">0036-8075:2001:De La Fuente Fernandez R:expectation:and:dopamine</idno>
<idno type="wicri:Area/Main/Merge">003814</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11498597</idno>
<idno type="wicri:Area/PubMed/Corpus">001557</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001557</idno>
<idno type="wicri:Area/PubMed/Curation">001557</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001557</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001557</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001557</idno>
<idno type="wicri:Area/Ncbi/Merge">000175</idno>
<idno type="wicri:Area/Ncbi/Curation">000175</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000175</idno>
<idno type="wicri:doubleKey">0036-8075:2001:De La Fuente Fernandez R:expectation:and:dopamine</idno>
<idno type="wicri:Area/Main/Merge">003585</idno>
<idno type="wicri:Area/Main/Curation">003326</idno>
<idno type="wicri:Area/Main/Exploration">003326</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease</title>
<author><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 285</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 285</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, University of British Columbia</s1>
<s2>Vancouver, BC, Canada V6T 285</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC, Canada V6T 285</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Science : (Washington, D.C.)</title>
<title level="j" type="abbreviated">Science : (Wash. D.C.)</title>
<idno type="ISSN">0036-8075</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Science : (Washington, D.C.)</title>
<title level="j" type="abbreviated">Science : (Wash. D.C.)</title>
<idno type="ISSN">0036-8075</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Corpus Striatum (diagnostic imaging)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus striatum</term>
<term>Dopamine</term>
<term>Dopamine (metabolism)</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Placebo Effect</term>
<term>Placebo effect</term>
<term>Placebos (administration & dosage)</term>
<term>Raclopride (metabolism)</term>
<term>Release</term>
<term>Synapses (metabolism)</term>
<term>Tomography, Emission-Computed</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Placebos</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Raclopride</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Corpus Striatum</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Parkinson Disease</term>
<term>Synapses</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Placebo Effect</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Libération</term>
<term>Dopamine</term>
<term>Corps strié</term>
<term>Voie nigrostriatale</term>
<term>Effet placebo</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Placebo</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The power of placebos has long been recognized for improving numerous medical conditions such as Parkinson's disease (PD). Little is known, however, about the mechanism underlying the placebo effect. Using the ability of endogenous dopamine to compete for [<sup>11</sup>
C]raclopride binding as measured by positron emission tomography, we provide in vivo evidence for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo. Our findings indicate that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name>
</noRegion>
<name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003326 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003326 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:01-0457641
   |texte=   Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease

Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.